Repligen Corp vs Eli Lilly & Co.
RGEN vs LLY — side-by-side comparison from reported financials. RGEN leads 1, LLY leads 9 of 10 comparable metrics.
Repligen Corp
RGEN · Healthcare
$173.88+6.13%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | RGEN | LLY |
|---|---|---|
| Price | $173.88 | $1 177.20 |
| Market cap | $11.0B | $1.05T |
| Revenue (TTM) | $785M | $79.7B |
| Revenue growth | -2.7% | +31.7% |
| Net margin | 5.3% | 33.5% |
| Free cash flow | $112M | $18.2B |
| Net cash (debt) | $225M | ($35.2B) |
| 1-year price return | +16.8% | +37.6% |
| P/E | 265.8 | 41.6 |
| P/E vs own history (cheap-side %) | 2% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 2% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 7 of 10 | 11 of 10 |
| Employees | 2,000 | 50,000 |
Full résumé-style profiles: RGEN CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.